5 Key Takeaways
-
1
ten23 health and BD have partnered to commercialize the BD Libertas™ wearable injector for self-administered therapies.
-
2
The collaboration aims to provide biopharma companies with a fully integrated solution for subcutaneous delivery of large-volume drugs.
-
3
ten23 health will offer process development, aseptic filling, assembly, and quality control services to support the injector's use.
-
4
The partnership includes a testing facility, Line 0, allowing customers to optimize processes without GMP production delays.
-
5
The BD Libertas™ injector facilitates the transition of biologics from IV to SC delivery, enhancing patient experience and regulatory pathways.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
